Trial Profile
PHASE II TRIAL OF THE mTOR INHIBITOR EVEROLIMUS IN RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Therapeutic Use
- 24 Apr 2016 Status changed from recruiting to discontinued due to Poor enrolment.
- 22 Jul 2014 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov.
- 16 Jul 2012 New trial record